[go: up one dir, main page]

MX2017009091A - Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad. - Google Patents

Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Info

Publication number
MX2017009091A
MX2017009091A MX2017009091A MX2017009091A MX2017009091A MX 2017009091 A MX2017009091 A MX 2017009091A MX 2017009091 A MX2017009091 A MX 2017009091A MX 2017009091 A MX2017009091 A MX 2017009091A MX 2017009091 A MX2017009091 A MX 2017009091A
Authority
MX
Mexico
Prior art keywords
desferrioxamine
immune
metal complexes
treatment
dfo
Prior art date
Application number
MX2017009091A
Other languages
English (en)
Inventor
Vladimir Vinokur
Eduard Berenshtein
Mordechai Chevion
Ron Eliashar
Baruch Bulvik
Original Assignee
Mordechai Chevion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mordechai Chevion filed Critical Mordechai Chevion
Publication of MX2017009091A publication Critical patent/MX2017009091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos, kits y composiciones combinadas que utilizan complejos de DFO-metal, especialmente, complejos de zinc-desferroxiamina (Zn-DFO), galio-desferroxiamina (Ga-DFO) y cualquier combinación de los mismos para prevenir tratar, mejorar o inhibir un trastorno relacionado con la inmunidad, especialmente, un trastorno inflamatorio relacionado con la piel tal como psoriasis, una condición respiratoria inflamatoria tal como asma, y una enfermedad autoinmunitaria tal como diabetes y cualquier trastorno relacionado con la inmunidad.
MX2017009091A 2009-08-19 2012-02-14 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad. MX2017009091A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23506209P 2009-08-19 2009-08-19
US29859610P 2010-01-27 2010-01-27
US34761710P 2010-05-24 2010-05-24

Publications (1)

Publication Number Publication Date
MX2017009091A true MX2017009091A (es) 2021-03-25

Family

ID=43259672

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001967A MX349387B (es) 2009-08-19 2010-08-19 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.
MX2017009091A MX2017009091A (es) 2009-08-19 2012-02-14 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012001967A MX349387B (es) 2009-08-19 2010-08-19 Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.

Country Status (10)

Country Link
US (2) US8975294B2 (es)
EP (2) EP3189836B1 (es)
JP (1) JP2013502407A (es)
CN (1) CN102573831A (es)
AU (2) AU2010286054B2 (es)
BR (1) BR112012003447A2 (es)
CA (1) CA2771257C (es)
IL (1) IL253293B (es)
MX (2) MX349387B (es)
WO (1) WO2011021203A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
JP2013123450A (ja) * 2011-12-13 2013-06-24 Akihiro Sato 金属錯体イオン液を応用した塵肺の療養方法、および、咽頭・気管・気管支の療養方法
AU2015369552B2 (en) * 2014-12-22 2020-11-19 Eduard Berenshtein New metal complexes of nocardamine and their use in pharmaceutical compositions
SG11201806157WA (en) 2016-02-11 2018-08-30 Mordechai Chevion Method and pharmaceutical composition for treatment of neurodegeneration
WO2018039488A1 (en) * 2016-08-24 2018-03-01 Wisconsin Alumni Research Foundation Siderophore-polymer conjugates for increasing bacterial sensitivity to antibiotics
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CA3095122A1 (en) * 2018-03-27 2019-10-03 Tautona Group Ip Holding Company, L.L.C. Topical and transdermal delivery of an iron chelator to prevent and treat chronic wounds
AU2019253059A1 (en) * 2018-04-13 2020-11-12 Mordechai Chevion Compositions and methods for treatment of demyelination
EP3781143A4 (en) * 2018-04-15 2022-01-05 Mordechai Chevion COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRON OVERLOAD
EP4061402A4 (en) 2019-11-20 2023-12-06 The Board of Trustees of the Leland Stanford Junior University PROPHYLACTIC SKIN TREATMENT FOR RADIATION THERAPY
WO2022015983A1 (en) * 2020-07-15 2022-01-20 Memorial Sloan-Kettering Cancer Center Methods of treating leptomeningeal metastasis
CN114460163B (zh) * 2022-02-11 2023-03-03 河北师范大学 一种检测生物组织铁含量的maldi质谱成像方法
US20240079111A1 (en) * 2022-08-24 2024-03-07 Insulet Corporation System and method for adjusting insulin delivery to account for insulin resistance
WO2024241250A2 (en) * 2023-05-22 2024-11-28 Vladimir Vinokur Novel composition for treatment of inflammatory related disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
IL91047A (en) * 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
IL106064A (en) * 1993-06-18 1997-11-20 Yissum Res Dev Co Gallium complexes for the treatment of free radical-induced diseases
AU6031096A (en) * 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
CA2206203A1 (en) * 1997-05-27 1998-11-27 University Of British Columbia Photoactivation of endogenous porphyrins for treatment of psoriasis
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
FR2825920B1 (fr) 2001-06-15 2006-04-28 Oreal Desferal comme inhibiteur de no-synthase et utilisations
AU2003290393A1 (en) * 2003-01-07 2004-07-29 Hadasit Medical Research Services & Development Ltd. Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent
CA2526971A1 (en) * 2003-06-04 2005-01-06 Ebersytes, Llc Novel dermatological composition
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD OF TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF ACUTE INCREASES IN HYPERGLYCEMIA AND / OR ACUTE INCREASES OF FREE FATTY ACID FLOWS
US8680148B2 (en) * 2006-08-11 2014-03-25 University Of Washington Metallo-desferrioxamine complexes and their use in the treatment of bacterial infections
WO2008061299A1 (en) * 2006-11-21 2008-05-29 Garvan Institute Of Medical Research Method of treating diabetes

Also Published As

Publication number Publication date
MX2012001967A (es) 2012-07-17
US9770430B2 (en) 2017-09-26
WO2011021203A3 (en) 2011-04-14
US20120220651A1 (en) 2012-08-30
EP3189836A2 (en) 2017-07-12
BR112012003447A2 (pt) 2018-03-20
MX349387B (es) 2017-07-05
WO2011021203A2 (en) 2011-02-24
CA2771257C (en) 2018-09-18
CA2771257A1 (en) 2011-02-24
US20150148413A1 (en) 2015-05-28
EP2467135B1 (en) 2017-02-01
IL253293A0 (en) 2017-09-28
JP2013502407A (ja) 2013-01-24
IL253293B (en) 2020-01-30
AU2016244189A1 (en) 2016-10-27
EP3189836B1 (en) 2024-01-17
AU2010286054A1 (en) 2012-03-08
AU2016244189B2 (en) 2018-06-28
AU2010286054B2 (en) 2016-10-27
US8975294B2 (en) 2015-03-10
CN102573831A (zh) 2012-07-11
EP3189836A3 (en) 2017-09-27
EP2467135A2 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
MX2017009091A (es) Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.
EA020330B3 (ru) Хиназолиновые соединения
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
SG179038A1 (en) Compositions and methods for diagnosing autism spectrum disorders
MY165582A (en) Azetidine and cyclobutane derivatives as jak inhibitors
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12017500864A1 (en) Anti-notch1 antibodies
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
PH12012501768A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
IN2012DN00624A (es)
MX355325B (es) Quinazolincarboxamida azetidinas.
WO2010006130A3 (en) Pde-10 inhibitors
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
IN2015KN00492A (es)
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
MX2010004814A (es) Metodos para tratar esclerodermia.
HK1201523A1 (en) Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a